Your browser doesn't support javascript.
loading
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation.
Nikiforow, Sarah; Kim, Haesook T; Daley, Heather; Reynolds, Carol; Jones, Kyle Thomas; Armand, Philippe; Ho, Vincent T; Alyea, Edwin P; Cutler, Corey S; Ritz, Jerome; Antin, Joseph H; Soiffer, Robert J; Koreth, John.
  • Nikiforow S; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA sarah_nikiforow@dfci.harvard.edu.
  • Kim HT; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard School of Public Health, Boston, MA, USA.
  • Daley H; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Reynolds C; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Jones KT; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Armand P; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ho VT; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Alyea EP; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Cutler CS; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ritz J; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Antin JH; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Soiffer RJ; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Koreth J; Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA.
Haematologica ; 101(10): 1251-1259, 2016 10.
Article en En | MEDLINE | ID: mdl-27354021
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T Reguladores / Transfusión de Linfocitos / Neoplasias Hematológicas / Efecto Injerto vs Tumor / Subunidad alfa del Receptor de Interleucina-2 Tipo de estudio: Etiology_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T Reguladores / Transfusión de Linfocitos / Neoplasias Hematológicas / Efecto Injerto vs Tumor / Subunidad alfa del Receptor de Interleucina-2 Tipo de estudio: Etiology_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article